A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Author:

Assi Rita1ORCID,Kantarjian Hagop M.1ORCID,Garcia-Manero Guillermo1,Cortes Jorge E.1,Pemmaraju Naveen1ORCID,Wang Xuemei2,Nogueras-Gonzalez Graciela2,Jabbour Elias1ORCID,Bose Prithviraj1,Kadia Tapan1ORCID,Dinardo Courtney D.1ORCID,Patel Keyur3,Bueso-Ramos Carlos3,Zhou Lingsha1,Pierce Sherry1,Gergis Romany1,Tuttle Carla1,Borthakur Gautam1,Estrov Zeev1,Luthra Rajyalakshmi3,Hidalgo-Lopez Juliana3ORCID,Verstovsek Srdan1,Daver Naval1ORCID

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Department of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston Texas

3. Department of Hematopathology; The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

Incyte Pharmaceuticals

Cancer Centre Leukaemia Support Grant

University of Texas MD Anderson Cancer Center

Charif Souki Cancer Research Fund and generous philanthropic contributions to the MD Anderson Moon Shots Program

Publisher

Wiley

Subject

Hematology

Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3